VANCOUVER, CANADA – June 20, 2013 – Evasc today announced their first clinical deployment and successful implant of the eCLIPs Bifurcation Remodeling System in a human patient. The case was performed under Health Canada’s Special Access Program.
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases, and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters, and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac, while protecting and providing a platform for endothelial growth across the bifurcation neck.
“After very successful animal trials, the first deployment of eCLIPs in a human patient is a major milestone for Evasc”, said Dr. Donald Ricci, President and Chief Executive Officer of Evasc. “We are excited to have been able to contribute to the success of this intervention, and look forward to many more.”
Evasc is a privately-held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc is headquartered in Vancouver, Canada.
Evasc is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, email@example.com.